Debate 1: Should Metformin remain the „foundation therapy“ for the majority of patients with T2D?

In a debate moderated by Professor Inzucchi, Professor Giorgino takes the position that metformin should remain as the “foundation therapy” for the majority of patients with T2D. Professor Marx takes the opposing position that metformin should not remain as the “foundation therapy” for the majority of patients with T2D.